Dra. Marianela Aguirre Ackermann

Medicine, Diabetes, Obesity, Nutrition, Internal Medicine, Bariatric & Metabolic Surgery

[Cristina Tejera @cristinatejerap]

Los factores de riesgo clásicos no explican toda la enfermedad cardiovascular en mujeres. La obesidad abdominal y la inflamación crónica de bajo grado aceleran la aterosclerosis, y su impacto es mayor en nosotras. Toca mirar más allá de los factores de riesgo clásicos 🫀

🔗 https://t.co/Gdq18NsPYV

[Ali Aminian @Ali_Aminian_MD]

Great work and summary by @carel_leroux

[Daniel J Drucker @DanielJDrucker]

Here the authors propose prioritization of individuals with #obesity and a high risk for obesity associated complications for weight loss interventions https://t.co/QWpII6OGZ3

[Neil Floch MD @NeilFlochMD]

Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists | JAMA Surgery | JAMA Network #bariatricsurgery #obesity https://t.co/5Jpe5Za811

[Daniel J Drucker @DanielJDrucker]

SURMOUNT-OSA Weight loss drives a substantial proportion of benefit https://t.co/nsTq0WIbeL

[Dra. Mónica Katz @KatzDra]

Tenes alguna duda?

[Ricardo Cohen @rvcohen]

Thoughtful clarification by @FRubinoMD. The Commission’s framework is a new diagnostic model for obesity; some debate and confusion are natural as it evolves. Constructive dialogue helps move us toward clarity and progress and the best for all people living with obesity.

[Francesco Rubino @FRubinoMD]

We had to think differently about obesity Now it’s everyone else’s turn. Read @TIME how the @TheLancetEndo Commission redefined obesity in alignment with medical principles of disease diagnosis @WorldObesity @IfsoSecretariat @rvcohen @EricTopol @EASDnews

https://t.co/2JDPsr0hu6

[Beverly G. Tchang, MD @BevTchangMD]

Semaglutide plus trevogrumab (myostatin inhibitor) preserves muscle mass in the setting of #weightloss over 26 wks @Regeneron

Combination vs sema alone:

👉 #Weight ⬇️11.3% vs ⬇️10.4%

👉 Muscle ⬇️4.2 lbs vs ⬇️7.9 lbs

👉 Fat ⬇️18.9 lbs vs ⬇️15.3 lbs

https://t.co/EHXPQ5qeAl

[Dra. Mónica Katz @KatzDra]

Bravisimo!

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

Definition and diagnostic criteria of clinical #obesity https://t.co/cM8pyJ2UG9
#FREE to read with registration (also FREE)

[Ricardo Cohen @rvcohen]

This level 1A evidence shows that chronic kidney disease do not affect the safety and efficacy of RYGB and SG

[Ali Aminian @Ali_Aminian_MD]

🔥 14% body weight reduction with tirzepatide improved heart failure outcomes.

Presented at #AHA24

[Ricardo Cohen @rvcohen]

New paper just published. The Lancet. Lingvay, Cohen et al
https://t.co/VOFuygHmSY

[Dra. Marianela Aguirre Ackermann @dramarianelack]

Magnifico trabajo con Grupo Internacional de expertos, liderado por Arya Sharma
Gracias @amsharm !!

“Set ICHOM de Indicadores de Resultados para personas que viven con obesidad”  
https://t.co/EGd92wSDJf

Estos Indicadores nos ayudarán a mejorar la vida de nuestros pacientes

[InfoAlimentos @alimentos_info]

Interesantísimo esto que explica @deborahciencia .¿que bolsas deberíamos elegir para hacer las compras?👇

[Dra. Marianela Aguirre Ackermann @dramarianelack]

American Diabetes Association https://t.co/EDmGLSoCNZ
Sharing with colleagues from Latin America at excellent ADA 2024 congress!!👏👏👏

@ADA_DiabetesPro @AmDiabetesAssn

[Dra. Marianela Aguirre Ackermann @dramarianelack]

Qué es “comer con sentido” y por qué los especialistas lo recomiendan para la relación con la alimentación - Infobae https://t.co/isw38Z6uui

[Dra. Marianela Aguirre Ackermann @dramarianelack]

@FRubinoMD @InigoLND @ItalyinUK Congrats Francesco!! 👏👏👏

[Ali Aminian @Ali_Aminian_MD]

In patients with heart failure & #obesity:

Bariatric surgery: ⬇️ 45% risk of death

GLP-1 RA drugs: ⬇️ 18% risk of death

✨ The sad part of story: ONLY 1% of eligible patients undergo #bariatricsurgery

https://t.co/jxzbZ9zFU8